Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tumor markers Present; by Dr. Andalib Isfahan Medical School

Similar presentations


Presentation on theme: "Tumor markers Present; by Dr. Andalib Isfahan Medical School"— Presentation transcript:

1 Tumor markers Present; by Dr. Andalib Isfahan Medical School

2

3

4

5 Overview cancer is a broad term used to describe > 200 different diseases that affect 50 tissues.

6 What are Tumor Markers?
Biological substances synthesized and released by cancer cells themselves or produced by normal cells in response to tumor. Most tumor markers are proteins

7 Tumor Specific Transplantation Antigen (TSTA)
Tumor antigens Tumor Specific Transplantation Antigen (TSTA) Tumor Specific Antigen (TSA) Viral antigens proto oncogenes Viral Antigen : a- Viral proteins and glycoproteins b- New antigens produced by virally infected host cells under control of viral nucleic acid

8 Tumor antigens Tumor Associated Antigens (TAA) of certain cancerous tissue BUT large overlap tissue differentiation antigens gene products with increased expression altered glycoproteins and glycolipids Altered expression of gene products Oncofetal antigens Viral Antigen : a- Viral proteins and glycoproteins b- New antigens produced by virally infected host cells under control of viral nucleic acid

9 p. 526

10 Tumor antigens could be used for
Screening of disease. Diagnosis of symptomatic patients. Staging of cancers. Prognostic indicators. Detect recurrence in Follow-Up of disease. Monitoring response to therapy. low sensitivity and lack of specificity and relation to tumor size......limited role in screening The pre-therapeutic level of certain tumor marker can contributes a prognostic factor because of links with... Metabolic activity,Tumor size and Invasion

11 Tumor marker First tumour marker 1938
Acid phosphatase for metastatic prostate

12 Tumor markers Are biochemical substances which, as the name suggest, are closely associated with carcinogenesis Are substances, such as proteins, biochemical, or enzymes, produced by tumor cells or by the body cells in response to tumor cells Are substances that can often be detected in higher than normal in the blood, urine, or body tissues of some patients with certain types of cancer Substances present in or produced by a tumor itself or produced by the host in response to a tumor

13 Tumor markers Measurement of tumor markers: helpful
Tumor marker levels could elevated in benign conditions Many tumor markers are not specific to a particular type of cancer In addition diagnosis :help physicians make a plan for appropriate therapy

14 Tumor markers Used to differentiate tumor from normal tissue
Determine presence of tumor based on quantity in blood or secretions Higher quantity in cancer tissue, or in blood from cancer patient, then in benign tumors or normal individuals Few tumor markers are specific for a single type of tumor

15 Tumor markers Most markers are found in many different types of tumor
Monitor a patient response to treatment After treatment :as a part of follow up care to check for recurrence Decrease or return to normal: favorable response to therapy

16 Tumor marker classification
Tumor antigens Enzymes Hormones Oncogene products Oncofetal Receptors Genetic markers

17 Tumor antigens-Oncofetal
Oncofetal:produced during normal emberyogical development and by neoplastic cells Defined by polyclonal or monoclonal antibodies CEA, AFP, HCG

18 Tumor associated antigens (Cancer antigen)

19 ENZYMES Neuron specific enolase(NSE) Acid phosphatase
Lactic dehydrogenase

20 Dunn et al. Nature Reviews Immunology 6, 836–848 (November 2006) | doi:10.1038/nri1961

21 Hormones * Human Chorionic Gonadotrophins (HCG)
are secreted in Choriocarcinoma, Ovarian Cancer * Thyroxin is secreted in thyroid cancer

22 Ideal markers Present in early in disease
Before clinical evidence of disease Increase with advancing tumor Decrease with effective therapy Test reproducible Available and cost effective

23 Ideal marker Specific: produced only by cells of a particular malignancy and not by other cancers, or benign conditions Sensitive: produced in all patient with similar malignancy

24 Specific organ tumor systems
Gastrointestinal tumors CEA AFP CA19-9

25 Prostate specific antigen
PSA Prostate specific antigen

26 PSA In low concentration in the blood of all adult males
Is produced both normal and abnormal prostate cells Elevated PSA levels: in blood of men with benign prostate condition Prostatitis/benign hyperplasia/malignant

27 PSA PSA level:monitoring the effectiveness of prostate cancer treatment Checking recurrence after treatment

28 PSA As a screen for prostate cancer or in the elevation of or to follow up a person with prostate disease

29 Cancer antigen 27-29 For Breast cancer

30 CA 27-29 Breast cancer Check for recurrence in woman previously treated for stage 2 and stage 3 breast cancer Colon/stomach/kidney/lung/ovary/ pancreas/uterus/liver Nan-cancerous: first trimester pregnancy/endometritis/ovarian cysts/benign breast disease/kidney disease/liver disease

31 Title

32 Neuron-specific enolase Neuroblastoma
NSE Neuron-specific enolase Neuroblastoma

33 NSE Neuroblastoma/small cell lung cancer/wilms tumor/melanoma/cancers of thyroid/kidney/testicule/pancreas Patient prognosis Patient response to treatment

34 Carcino-Emberyonic Antigen
CEA Carcino-Emberyonic Antigen

35 CEA Oncofetal protein Normal during fetal life(low concentration in healthy adults) Higher concentration in some epithelial malignancies Glycoprotein(molecular weight 200,000KD)

36 CEA Found on cell membrane Easily released into fluids
Related to immunoglobolin super-family genes Normally found in mucus secretions of the stomach, small intestine

37 CEA Small amount in the blood of healthy people
Primary use of CEA: in monitoring colorectal cancer Melanoma/lymphoma/breast/lung/pancreas/stomach/cervix/bladder/kidney/thyroid/liver/ovary Nan-cancerous condition: inflammatory bowel disease/pancreatitis/liver disease Tobacco users

38 CEA lOW SPECIFICITY and lOW SENSITIVITY

39 AFP Alpha-fetoprotein

40 AFP First described oncofetal antigen Normally: by a developing fetus
AFP level :elevated :liver cancer/germ cell cancer/ovary/testicule Non-cancerous condition: benign liver condition /cirrohosis or hepatitis/pregnancy

41 CA 19-9 Cancer antigen 19-9

42 CA 19-9 A carbohydrated antigen detected by monoclonal antibodies
Pancreatic cancer Biliary tract cancer Billary tract disease pancreatitis

43 TUMOR MARKER Screening Diagnosis Prognosis monitoring

44 Cancer antigen 125 ovarian cancer

45 CA 125 Is produced by a variety of cells(ovarian cancer)
Is used primarily in the management and treatment of ovarian cancer In woman with ovarian cancer: chemotherapy

46 CA125 Falling CA125 levels generally indicates that cancer is responding to treatment Increasing CA125 levels during or after treatment: is not responding to therapy

47 CA 125 To monitor for recurrence of ovarian cancer
Uterus/cervix/pancease/liver/colon/breast/lung/digestive tract Non-cancerous condition: elevated CA125(endometriosis/pelvic inflammatory disease/peritonitis/liver disease Menstruation and pregnancy

48 Human chorionic gonadotropine
HCG Human chorionic gonadotropine

49 HCG Is produced by placenta during pregnancy
For screen choriocarcinoma Monitoring the treatment of trophoblastic disease Elevated HCG level:testis/ovary/liver/stomach/pancreas/ lung/pregnancy/marijuana

50 Cancer antigen 15-3 breast cancer

51 CA 15-3 In following the course of treatment in women diagnosis with breast cancer(advance) Early stage breast cancer Ovary/lung/prostate Non-cancerous condition: benign breast/ovarian disease /endometrisis/pelvic inflammatory disease/hepatitis Pregnancy

52 Tumor marker Screen and diagnose cancer Predicting prognosis
Monitor treatment observation for cancer recurrence

53

54

55

56

57 Realty No marker to date satisfy these criteria

58 Thank you


Download ppt "Tumor markers Present; by Dr. Andalib Isfahan Medical School"

Similar presentations


Ads by Google